99mTc-rBitistatin

99mTc-rBitistatin is a radiopharmaceutical being developed for in vivo imaging of acute thrombi and emboli[2]. It's a radioligand that binds to the αIIbβ3 (GPIIb/IIIa) receptor on platelets[2]. This compound has undergone Phase I clinical trials in normal human subjects to investigate its biodistribution, safety, and dosimetry[1].\n\n## Pharmacology and Mechanism of Action\n\n99mTc-rBitistatin specifically targets the GPIIb/IIIa receptor on platelets. No snake venom disintegrin had previously been administered to humans before this compound[2]. The radiopharmaceutical has shown the ability to bind to circulating platelets in humans, suggesting it can bind to activated platelets in vivo in patients with acute thrombi[2].\n\n## Pharmacokinetics\n\nIn human studies, 99mTc-rBitistatin follows a two-phase clearance pattern:\n- Approximately 83% leaves the blood with a half-life of 6.6 minutes\n- The remaining 17% leaves the blood with a half-life of 3.8 hours[2]\n\nAt 1 hour post-injection, about 44.3±0.4% of blood activity was platelet-bound, increasing to 75±5% at 6 hours and 85±4% at 24 hours as plasma activity cleared[2]. This binding profile differs from that observed in animal models, where higher percentages of binding to platelets were observed (e.g., in guinea pigs: 88%, 92%, and 95% of total blood activity bound to platelets at 1, 2, and 4 hours respectively)[2].\n\n## Clinical Development\n\nThe drug has undergone Phase I clinical trials to assess its safety and biodistribution in normal human subjects[1]. A Phase II investigation (NCT00808626) for imaging venous thrombosis has also been conducted[6].\n\nWhen administered at low doses for imaging purposes, 99mTc-rBitistatin has shown no adverse effects on platelets and demonstrates the qualitative biodistribution predicted by animal studies[2]. In animal models, 99mTc-labeled Bitistatin was found to concentrate in deep vein thrombosis (DVT) and pulmonary embolism (PE), providing focally positive gamma camera images of thrombi/emboli[2].\n\nCompared to other GPIIb/IIIa targeted radiotracers, labeled autologous platelets, or fibrin-targeted radiopharmaceuticals tested in the same animal model, 99mTc-Bitistatin had a higher percentage of injected dose bound per gram of thrombus/embolus and a higher target-to-background ratio with surrounding tissues[2].